The Odontoprev S.A. (BVMF:ODPV3) Yearly Results Are Out And Analysts Have Published New Forecasts

Last week, you might have seen that Odontoprev S.A. (BVMF:ODPV3) released its annual result to the market. The early response was not positive, with shares down 9.1% to R$10.61 in the past week. It was an okay result overall, with revenues coming in at R$2.3b, roughly what the analysts had been expecting. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

Check out our latest analysis for Odontoprev

After the latest results, the ten analysts covering Odontoprev are now predicting revenues of R$2.40b in 2025. If met, this would reflect a satisfactory 4.6% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to accumulate 2.9% to R$1.02. Before this earnings report, the analysts had been forecasting revenues of R$2.39b and earnings per share (EPS) of R$0.99 in 2025. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.

The consensus price target was unchanged at R$11.81, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Odontoprev analyst has a price target of R$14.00 per share, while the most pessimistic values it at R$10.00. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We can infer from the latest estimates that forecasts expect a continuation of Odontoprev'shistorical trends, as the 4.6% annualised revenue growth to the end of 2025 is roughly in line with the 4.8% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 9.7% per year. So although Odontoprev is expected to maintain its revenue growth rate, it's forecast to grow slower than the wider industry.

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Odontoprev following these results. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at R$11.81, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Odontoprev going out to 2027, and you can see them free on our platform here.

We don't want to rain on the parade too much, but we did also find 1 warning sign for Odontoprev that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.